Chronic graft-versus-host disease (cGvHD) is the single major factor influencing long-term outcome and quality of life after allogeneic transplantation. However, the presence of cGvHD has been linked to decrease in relapse rate of patients with CML, ALL, and AML. In a recent CIBMTR/NMDP analysis of ∼3500 transplant patients with cGvHD, risk of relapse was reduced by 50%. Traditionally, cGvHD has been defined as occurring after day + 100, this entity has been documented as early as 50 days to years after the transplant procedure. Chronic GvHD can emerge during or immediately following taper of immune suppressive agents or may occur as part of a continuous spectrum merging acute GvHD into cGvHD (progressive GvHD).
|Original language||English (US)|
|Title of host publication||Blood and Marrow Transplant Handbook|
|Subtitle of host publication||Comprehensive Guide for Patient Care|
|Publisher||Springer New York|
|Number of pages||24|
|State||Published - Dec 1 2011|
ASJC Scopus subject areas